Use-case library Pharmaceuticals & Biotech

Pharmaceuticals & Biotech

13 documented use cases: 5 quick wins, 5 medium-term, 3 transformational. Start at the top of the first band; do not start a transformational case as your first project.

Quick win · 5

Subscribe and configure, days to weeks on tools you can cancel monthly.

AI-Powered Literature Review and Scientific Summarisation

How it works: Before AI: Scientists spend 2-4 hours daily searching public biomedical databases, scholarly search engines, and proprietary databases for relevant publications, then manually reading, annotating, and summarising key findings. After AI: AI tools ingest search queries in natural language, retrieve and rank relevant papers by relevance and recency, extract key findings, and generate structured summaries with citations. Scientists review and refine AI outputs, spending 30-45 minutes instead of hours.
Impact: 76% of biotech companies already using AI for literature review (2026 report from a life-sciences software provider). Typical time savings: 60-70% reduction in literature review effort. One mid-size biotech reported saving 300 researcher-hours per month.
Tools: AI research assistant (free tier available)AI scholarly search engineAI evidence-synthesis assistantAI answer engine with academic focusAI productivity assistant with academic plugins
Roles touched: teaching

GenAI-Assisted Medical Writing and Document Drafting

How it works: Before AI: Medical writers spend days drafting clinical study reports, protocols, and regulatory documents from templates, manually pulling data from multiple sources and ensuring consistency across sections. After AI: AI assistants generate first drafts from structured data inputs (study synopses, statistical tables, safety databases), following regulatory formatting guidelines. Writers review, refine, and approve drafts, reducing turnaround from weeks to days.
Impact: A major pharmaceutical company reports 16,000 hours saved annually in research operations, with significant contribution from document automation. Medical writing cycle times reduced by 40-60% for standard documents.
Tools: AI writing assistant (enterprise license)AI content generation assistant (healthcare-focused)Enterprise conversational AI assistant (with appropriate data governance)Internal large language model deployments
Roles touched: teachingadmin

AI-Enhanced Adverse Event Processing and Case Intake

How it works: Before AI: Pharmacovigilance associates manually triage incoming adverse event reports from multiple channels (email, phone, literature, social media), extract relevant medical information, code events using a standardized medical coding dictionary, and create case narratives. After AI: AI systems automatically ingest reports, extract structured data, suggest standardized medical coding, draft initial case narratives, and flag cases requiring urgent medical review. Humans review AI outputs, correct errors, and handle complex cases.
Impact: Agentic AI is reclaiming up to 40% of pharmacovigilance capacity. Regulatory compliance (51%) is the highest-priority agentic AI use case in pharma. Case processing time reduced from hours to minutes for routine cases.
Tools: AI literature and signal detection toolpharmacovigilance safety database platformcloud-based safety management suitecustom NLP models on cloud infrastructure
Roles touched: operationsadmin

AI-Powered Meeting Summarisation and Action Tracking

How it works: Before AI: Administrative staff or rotating team members manually take meeting notes, often missing key decisions and action items. Follow-up is inconsistent. After AI: AI tools join virtual meetings, generate real-time transcripts, extract key decisions and action items, assign owners, and send automated follow-up reminders. Works with major video conferencing platforms.
Impact: Saves 3-5 hours per week for administrative staff. Improves action item completion rates by 30-40%. Ensures institutional memory for cross-functional project meetings.
Tools: AI meeting transcription and summarisation assistantAI note organisation assistant
Roles touched: admin

AI-Assisted Competitive Intelligence Monitoring

How it works: Before AI: Commercial and strategy teams manually track competitor pipeline updates, regulatory approvals, clinical trial results, and market developments across dozens of sources. After AI: AI platforms continuously monitor patent filings, public clinical trial registries, FDA/EMA databases, press releases, and scientific publications, generating real-time competitive intelligence dashboards with automated alerts.
Impact: Reduces competitive intelligence cycle time from weekly manual reports to real-time alerts. Strategy teams report spending 50% less time on data gathering and 50% more time on insight generation.
Tools: pharmaceutical market intelligence platformindustry data providerAI search assistantcustom AI agents monitoring RSS feeds
Roles touched: marketingleadership

Medium-term · 5

Needs data plumbing and integration, a quarter or two.

AI-Driven Clinical Trial Optimisation (Site Selection, Protocol Design, Patient Matching)

How it works: AI analyses historical trial data (enrolment rates by site, protocol amendment patterns, screen failure reasons) to optimise future trial designs. Specific applications include: predicting which sites will recruit fastest, identifying protocol elements that cause patient dropouts, matching eligible patients from electronic health records, and simulating trial outcomes under different design scenarios.
Impact: A major pharmaceutical company uses AI to analyse data from 460,000 historical trials and 700,000+ clinical sites. Early adopters report 70% reduction in trial costs and 25% faster enrolment. Potential to reduce trial timelines by 6-18 months. AI-enabled adaptive trial designs can reduce required patient numbers by 20-30%.
Tools: clinical trial data management platformclinical trial management systemtrial analytics platformtrial operations platformdigital twin simulation platform
Roles touched: operationsteaching

AI-Powered Molecular Design and Lead Optimisation

How it works: Generative AI models design novel molecular structures with desired properties (binding affinity, selectivity, ADMET profile, synthetic accessibility). Scientists specify target characteristics; AI proposes candidate molecules; wet-lab experiments validate top candidates. Iterative 'design-make-test-analyse' cycles become faster with each iteration as the AI learns from experimental results.
Impact: A major pharmaceutical company cut drug discovery timelines from years to 30 days in targeted applications through AI-powered molecular design. An AI drug-discovery firm’s fully AI-designed molecule reached Phase IIa in under 4 years. 50% of biotech report faster time-to-target with AI.
Tools: Molecular simulation softwareGenerative chemistry platformAI protein engineering toolMedicinal chemistry AI platformProtein structure prediction model
Roles touched: engineeringteaching

AI-Enhanced Regulatory Submission Preparation

How it works: AI tools assist in compiling, cross-referencing, and quality-checking regulatory submission dossiers (INDs, NDAs, MAAs). Specific applications: auto-populating Common Technical Document (CTD) modules from source data, checking consistency across submission sections, flagging potential regulatory questions based on historical agency feedback, and generating submission-ready tables and figures from clinical databases.
Impact: Regulatory submission preparation time reduced by 30-50% for standard submissions. AI-powered consistency checks reduce regulatory queries (deficiency letters) by identifying cross-section contradictions before submission.
Tools: Veeva Vault RIMIQVIA RIM SolutionsGeneris CARACustom NLP models for regulatory intelligence
Roles touched: adminleadership

AI-Enabled Pharmacovigilance Signal Detection

How it works: AI continuously monitors multiple data streams, spontaneous adverse event reports, social media, electronic health records, published literature, and clinical trial databases, to detect safety signals earlier than traditional statistical methods. Machine learning models identify patterns that may indicate previously unknown drug risks, prioritise signals for human review, and generate preliminary signal assessments.
Impact: AI-enhanced signal detection can identify safety signals weeks to months earlier than traditional methods. A major pharmaceutical company targets 50% efficiency gains in safety management by 2026. Earlier signal detection can prevent patient harm and reduce regulatory action risk.
Tools: pharmacovigilance signal detection platformdrug safety surveillance platformsafety case management platformcustom machine learning models for signal detection
Roles touched: operationsit

AI-Powered Supply Chain and Demand Forecasting

How it works: AI models analyse historical demand patterns, market dynamics, clinical trial enrolment projections, competitive market changes, and external factors (disease outbreaks, regulatory approvals, seasonal patterns) to predict drug demand at SKU and market level. Models also optimise manufacturing scheduling, inventory placement, and cold-chain logistics for temperature-sensitive biologics.
Impact: Demand forecast accuracy improvement of 15-25%. Inventory carrying costs reduced by 10-20%. Reduced product expiry waste, critical for biologics with limited shelf life. Equipment downtime reduced by 30-50% through predictive maintenance.
Tools: AI-powered supply chain planning platformdemand forecasting platformreal-time supply chain orchestration platformcustom forecasting models
Roles touched: operationsfinance

Transformational · 3

Restructures how the business works, years, and not a first project.

End-to-End AI-Native Drug Discovery Platform

How it works: A fully integrated AI platform that connects target identification, molecular design, ADMET prediction, synthesis planning, and early clinical trial design into a continuous feedback loop. Rather than using AI for individual tasks, the organisation redesigns the entire drug discovery process around AI capabilities, with human scientists providing strategic direction, biological validation, and creative insight.
Impact: Potential to reduce drug discovery timelines from 4-5 years to 1-2 years and costs from $500M+ to sub-$100M for early discovery stages. 173+ AI-discovered drug programmes now in clinical development. 15-20 expected to enter pivotal trials in 2026. A leading consultancy estimates $15-28 billion annual savings in research alone.
Tools: AI drug discovery platformAI research automation and screening platformMolecular simulation and modeling software suiteFederated learning platform for drug discoveryCustom integrated platforms built on cloud AI infrastructure
Roles touched: engineeringleadership

Agentic AI-Driven Regulatory and Compliance Operations

How it works: Autonomous AI agents handle multi-step regulatory workflows: monitoring regulatory changes across global jurisdictions, assessing impact on current products and pipeline, drafting required updates to labels and submissions, managing variation filing timelines, and coordinating cross-functional review processes. Human experts set the strategic framework and review critical decisions, while AI agents handle the operational execution.
Impact: 73% of pharma organisations are planning, piloting, or deploying agentic AI. Regulatory compliance (51%) is the highest-priority use case. Potential to handle 60-70% of routine regulatory maintenance autonomously, freeing regulatory affairs professionals for strategic work. Estimated 40% capacity recovery in pharmacovigilance through agentic automation.
Tools: life-sciences customer relationship platform with AI agent capabilitiesregulatory information management system with AI automationcustom agentic workflows on enterprise AI platforms
Roles touched: leadershipit

AI-Enabled Personalised Medicine and Companion Diagnostics

How it works: AI models integrate genomic, proteomic, metabolomic, and clinical data to identify patient subpopulations most likely to respond to specific therapies. This enables precision medicine approaches where drugs are developed and prescribed based on individual patient biomarker profiles. Companion diagnostics (AI-powered tests that identify eligible patients) are developed alongside the drug, creating a treatment-diagnostic pair.
Impact: Personalised medicine approaches can increase clinical trial success rates from ~10% (industry average) to 20-30% for biomarker-selected populations. Reduces wasted treatment (patients receiving drugs unlikely to work for them). Creates premium pricing opportunities for targeted therapies. A large pharmaceutical company’s clinical genomic database (800,000+ profiles, 150+ tumour subtypes) demonstrates the scale of data required.
Tools: genomic analysis platformclinical data AI platformAI diagnostic testing platformcustom multi-omics AI models
Roles touched: engineeringteaching

Ready to pick yours? Lesson eleven of the course walks the selection method step by step.

Pick one real bottleneck